Retatrutide is classified as a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors), making it more effective for body fat mass reduction than its predecessor Semaglutide by targeting further receptors
Mostly hunger/cravings and portion control discuss GLP-1 options (if medically appropriate)
Side Effects Comparison Both medications share similar side effect profiles since they belong to the same drug class, but the frequency and intensity can vary
Delaying can make constipation worse
Patients on Medicare who wanted Wegovy or Zepbound for chronic weight management typically paid full cash price, often $1,000 to $1,500 per month, putting these medications out of reach for most fixed-income beneficiaries
Others coordinate with employment changes offering better coverage